MARC 닫기

• LDR

  04123cam a2200565Ii 4500

• 001

  000001334195

• 005

  20210114163051

• 006

  m d

• 007

  cr |n|||||||||

• 008

  190918t20192019dcua od 000 0 eng d

• 019

  ▼a  1117822227

• 020

  ▼a  9780309490870
  ▼q  (electronic bk.)

• 020

  ▼a  0309490871
  ▼q  (electronic bk.)

• 020

  ▼a  9780309490894
  ▼q  (electronic bk.)

• 020

  ▼a  0309490898
  ▼q  (electronic bk.)

• 020

  ▼z  0309490863

• 020

  ▼z  9780309490863

• 035

  ▼a  2264533
  ▼b  (N$T)

• 035

  ▼a  (OCoLC)1119758025
  ▼z  (OCoLC)1117822227

• 040

  ▼a  YDX
  ▼b  eng
  ▼e  rda
  ▼e  pn
  ▼c  YDX
  ▼d  LVT
  ▼d  N$T
  ▼d  CUS
  ▼d  248023

• 050

  ▼a  RC268.3

• 050

  ▼a  RM262

• 082

  ▼a  616.994079
  ▼2  23

• 100

  ▼a  Balogh, Erin,
  ▼e  rapporteur.

• 245

  ▼a  Advancing progress in the development of combination cancer therapies with immune checkpoint inhibitors:
  ▼b  proceedings of a workshop /:
  ▼c  Erin Balogh and Sharyl J. Nass, Rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine.

• 260

  ▼a  Washington, DC:
  ▼b  the National Academies Press,
  ▼c  [2019].

• 300

  ▼a  1 online resource (xiiii, 65 pages):
  ▼b  color illustrations.

• 336

  ▼a  text
  ▼b  txt
  ▼2  rdacontent

• 337

  ▼a  computer
  ▼b  c
  ▼2  rdamedia

• 338

  ▼a  online resource
  ▼b  cr
  ▼2  rdacarrier

• 504

  ▼a  Includes bibliographical references.

• 520

  ▼a  "In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g., cancer cells, microorganisms). However, cancer cells can coopt these "checkpoint" proteins and thwart the immune system's ability to recognize and attack cancer cells. To help promote an immune response to cancer, researchers have developed immune checkpoint inhibitors that enable T-cells to recognize cancer cells as foreign and to prevent deactivation of an immune system response. To examine the challenges and opportunities to develop combination cancer therapies that include immune checkpoint inhibitors, the National Cancer Policy Forum held a workshop on July 16-17, 2018, in Washington, DC. This workshop convened stakeholders with a broad range of expertise, including cancer researchers, clinicians, patient advocates, and representatives from industry, academia, and government. This publication summarizes the presentations and discussions from the workshop"--Publisher's description

• 588

  ▼a  Online resource; title from PDF title page (National Academies Press, viewed September 10, 2019).

• 590

  ▼a  Master record variable field(s) change: 050, 650

• 650

  ▼a  Chemotherapy, Combination
  ▼v  Congresses.

• 650

  ▼a  Cancer
  ▼x  Treatment
  ▼v  Congresses.

• 650

  ▼a  Cancer
  ▼x  Immunotherapy
  ▼v  Congresses.

• 650

  ▼a  Cancer
  ▼x  Chemotherapy
  ▼v  Congresses.

• 650

  ▼a  Cancer
  ▼x  Immunological aspects.

• 655

  ▼a  Electronic books.

• 700

  ▼a  Nass, Sharyl J.,
  ▼e  rapporteur.

• 710

  ▼a  National Cancer Policy Forum (U.S.),
  ▼e  issuing body.

• 711

  ▼a  Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors (Workshop)
  ▼d  (2018 :
  ▼c  Washington, D.C.),
  ▼j  author.

• 776

  ▼i  Print version:
  ▼a  National Academies of Sciences, Engineering, and Medicine.
  ▼t  Advancing progress in the development of combination cancer therapies with immune checkpoint inhibitors.
  ▼d  Washington, DC: National Academies Press,
  ▼c  2019.,
  ▼z  0309490863
  ▼w  (OCoLC)1111642469

• 856

  ▼3  EBSCOhost
  ▼u  http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=2264533

• 938

  ▼a  YBP Library Services
  ▼b  YANK
  ▼n  16446135

• 938

  ▼a  EBSCOhost
  ▼b  EBSC
  ▼n  2264533

• 990

  ▼a  강리원

• 991

  ▼a  eBook

• 994

  ▼a  92
  ▼b  N$T